Syndax Pharmaceuticals: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Syndax Pharmaceuticals (NASDAQ:SNDX) reported Q4 earnings with an EPS of $-1.0, missing estimates by -1.0% against an expected $-0.99. Revenue remained unchanged from the same period last year. In the previous quarter, the company exceeded EPS estimates by $0.05, leading to a 0.0% share price increase the following day.
February 27, 2024 | 9:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Syndax Pharmaceuticals reported a slight miss in Q4 earnings with an EPS of $-1.0 against an estimate of $-0.99, and no change in revenue from the previous year.
The slight miss in earnings expectations for SNDX, combined with stagnant revenue, could lead to negative investor sentiment in the short term. Historically, the company's stock price did not react to a positive earnings surprise last quarter, indicating that even minor misses might negatively impact investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100